Latest news

ManufacturingJuly 23, 2026

Novo Nordisk Sues Eli Lilly Over GLP-1 Drug Advertising Claims

Novo Nordisk has filed a lawsuit against Eli Lilly in U.S. District Court in New Jersey, accusing its rival...

InsightsJuly 23, 2026

The End of Siloed Drug Development

Executive Summary Drug development has never been more scientifically advanced—or more operationally complex. Pharmaceutical companies are simultaneously managing increasingly sophisticated therapeutic...

ClinicalJuly 23, 2026

Due to poor phase 2 data, Agios declares goodbye to the sickle cell program

Agios Pharmaceuticals has abandoned an indication for its next-generation activator of pyruvate kinase (PK) in sickle cell disease (SCD)...

ClinicalJuly 23, 2026

Novartis Lets Go of Phase 2 Radioligand Therapy Following Clinic Disappointment

Novartis has ended development of one of its radioligand therapy (RLT) candidates after less-than-stellar clinical results halted its progress. The...

Research & DevelopmentJuly 22, 2026

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

Summit Therapeutics and its partner Akeso have released updated...

TechnologyJuly 22, 2026

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

The U.S. Food and Drug Administration (FDA) granted Johnson...

InsightsJuly 20, 2026

Top 10 Metrics Pharma Leaders Should Track During Digital Transformation

Executive Summary Digital transformation has become one of the pharmaceutical industry's most significant strategic priorities. Companies are investing billions in...

UncategorizedJuly 20, 2026

Sarclisa Escena Wins FDA Approval for Subcutaneous Use in Multiple Myeloma

Sanofi has received approval from the U.S. Food and Drug Administration for Sarclisa Escena, a subcutaneous formulation of its...

ClinicalJuly 20, 2026

Bausch + Lomb Ends BL1107 Glaucoma Program After Phase 2 Trial Misses Main Goal

Bausch + Lomb has decided to discontinue development of its investigational glaucoma eye drop BL1107 after the treatment failed...

Research & DevelopmentJuly 20, 2026

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

The Advanced Research Projects Agency for Health (ARPA-H) has...

CommercialJuly 20, 2026

GSK views the Hansoh-partnered ADCs’ phase 3 victory in China as confirming its “priority asset.”

Hansoh Pharmaceutical's two eagerly awaited ADCs have continued to...

InsightsJuly 20, 2026

The Return of M&A as a Growth Strategy in Biopharma

Executive Summary Mergers and acquisitions (M&A) have long played a central role in shaping the global biopharmaceutical industry. For decades, pharmaceutical...

InsightsJuly 20, 2026

Top 10 Reasons Pharma Companies Are Building Internal AI Governance Teams

Executive Summary Artificial intelligence (AI) is rapidly becoming embedded across the pharmaceutical value chain. From drug discovery and clinical development...

InsightsJuly 20, 2026

Why Traditional Pharma Marketing Models Are Being Rewritten

Traditional Pharma:Executive Summary The pharmaceutical industry's commercial model is undergoing one of its most significant transformations in decades. For years, pharmaceutical...